Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

doi:10.3748/wjg.v27.i19.2415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8477)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

717

WORD

195

HTML

5992

Figures (1-3)

220

Tables (1-2)

203

Sum=7327

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

387

Download

763

Sum=1150

May 21, 2021 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. May 21, 2021; 27(19): 2415-2433
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2415

Full Size Figure Download Figure

Figure 2 Response rates of first-line systemic therapy in patients with advanced hepatocellular carcinoma. A: Network diagram; B: Interventions ranked by P value with risk ratios and 95% confidence interval for overall response rate for each treatment vs lenvatinib. CI: Confidence interval; GEMOX: Gemcitabine and oxaliplatin; ORR: Overall response rate; RR: Risk ratio.

Citation: Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433
URL: https://www.wjgnet.com/1007-9327/full/v27/i19/2415.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i19.2415